Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Cancer immunotherapy, which leverages features of the immune system to target neoplastic
cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly …

Immune checkpoint blockade (ICB) therapy, while achieving tremendous clinical successes,
still suffers from a low objective response rate in clinical cancer treatment. As a proof-of …

Abstract Background Immune checkpoint inhibitors (ICIs) have activity across many tumor
types, but activation of the immune system may also lead to significant, often steroid …

Background Cytokines have been reported to alter the response to immune checkpoint
inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations …

Immune checkpoint inhibitors (ICIs) have proven effective in the treatment of numerous
cancers; however, they have been associated with immune-related adverse events (irAEs) …

Hyperactivation of PI3K/AKT/mTOR and MAPK/MEK/ERK signaling pathways is commonly
observed in many cancers, including triple-negative breast cancer (TNBC) and melanoma …

There have been major advances in the immunotherapy of cancer in recent years, including
the development of T cell engagers—antibodies engineered to redirect T cells to recognize …

Cancer immunotherapies can successfully activate immune responses towards certain
tumors. However, this can also result in the development of treatment-induced immune …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …